Maryland Health Care Commission

Buyer seeks actuarial consulting services to analyze the impact of requiring health insurers to cover pharmacogenomic testing. The study will evaluate social, medical, and financial impacts of mandating coverage for genetic testing that evaluates medication efficacy for depression or anxiety treatment. Buyer requires comprehensive analysis of how this mandate would affect insurance premiums, healthcare costs, and patient outcomes. The contractor will deliver a detailed report and present findings at a Commission meeting.

• 4/22/2025 - RFP Issue Date
• 5/16/2025 - Proposal Due Date
• 10/17/2025 - Final Report Due
• 11/20/2025 - Commission Presentation
• 12/1/2025 - Contract Period End

• Five years experience with actuarial estimates on coverage requirements
• Experience assessing clinical benefits of health care treatments
• Experience analyzing data from Maryland's MCDB or similar source

• Conduct social impact evaluation of pharmacogenomic testing coverage
• Perform medical evaluation of pharmacogenomic testing efficacy
• Estimate financial impact on carriers and consumers
• Conduct carrier surveys regarding insurance coverage policies
• Analyze data from Maryland's Medical Care Database
• Develop detailed report with findings and recommendations
• Create work plan with milestones and resource assignments
• Provide biweekly progress reports
• Deliver presentation at Commission meeting
• Evaluate how coverage affects appropriate use of service